Tempus AI, Inc. (NASDAQ:TEM) Short Interest Update

Tempus AI, Inc. (NASDAQ:TEM) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 8,730,000 shares, a growth of 42.2% from the December 15th total of 6,140,000 shares. Currently, 17.8% of the shares of the stock are sold short. Based on an average trading volume of 2,340,000 shares, the short-interest ratio is currently 3.7 days.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wolfe Research began coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Piper Sandler reissued a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Loop Capital reduced their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday. Bank of America increased their price target on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Finally, Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and lifted their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $56.36.

Insider Transactions at Tempus AI

In other Tempus AI news, COO Ryan Fukushima sold 120,000 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00. Following the completion of the sale, the chief operating officer now owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This represents a 10.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the transaction, the executive vice president now owns 246,085 shares in the company, valued at approximately $10,431,543.15. This represents a 17.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 865,041 shares of company stock valued at $35,917,673 over the last ninety days.

Institutional Trading of Tempus AI

Hedge funds have recently made changes to their positions in the business. First Horizon Advisors Inc. purchased a new stake in Tempus AI during the 3rd quarter worth approximately $30,000. FNY Investment Advisers LLC purchased a new stake in shares of Tempus AI during the fourth quarter worth $67,000. Sandia Investment Management LP purchased a new stake in shares of Tempus AI during the second quarter worth $136,000. Vestor Capital LLC acquired a new stake in shares of Tempus AI in the third quarter valued at $153,000. Finally, Stifel Financial Corp purchased a new position in Tempus AI in the third quarter valued at $218,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Stock Performance

TEM opened at $34.75 on Friday. The stock’s 50-day moving average price is $46.80 and its 200 day moving average price is $47.09. Tempus AI has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.